PROGRAM CHAIR
Anton P. Porsteinsson, MD
William B. and Sheila Konar Professor of Psychiatry
Neurology, Neuroscience, and Medicine
Director, Alzheimer’s Disease Care, Research and Education Program (AD CARE)
University of Rochester School of Medicine and Dentistry
Rochester, New York
PATIENT
Steve Bancroft
Rochester, New York
PROGRAM OVERVIEW
This program has been developed to educate health care practitioners who care for patients with Alzheimer’s disease on the importance of early diagnosis of mild cognitive impairment (MCI) due to Alzheimer’s disease, timely specialist referral, and effective treatment and monitoring of patients receiving anti-amyloid therapies. It highlights the importance of a multidisciplinary, shared decision-making approach to optimize care management. This Day in the Life docuseries provides unique insights into the patient’s journey from diagnosis to treatment and the physician’s perspective on the clinical strategies for managing disease symptoms.
TARGET AUDIENCE
This activity is designed to meet the educational needs of health care providers involved in the diagnosis and continued care of patients with Alzheimer’s disease, including primary care physicians, neurologists, geriatricians, psychiatrists, and other multidisciplinary team members.
LEARNING OBJECTIVES
On completing this program, attendees should be able to:
- Integrate evidence-based pathways for screening, diagnosing, and staging MCI and AD
- Appraise clinical practice recommendations informing use of DMTs for AD and identifying those who qualify for treatment based on available clinical data
- Assess and manage potential adverse events associated with DMTs for AD using a multidisciplinary approach
- Apply best practices for shared decision making when discussing DMT treatment for AD, including discussions of treatment benefits, risks, and what to expect with therapy
JOINT ACCREDITATION STATEMENT
In support of improving patient care, Med Learning Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 0.50 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
NURSES (ANCC) CREDIT DESIGNATION
Med Learning Group designates this activity for a maximum of up to 0.50 ANCC contact hours.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIPS
| Speaker | Relationship | Manufacturer |
| Anton P. Porsteinsson, MD | Consultant | Acadia, Athira Pharma, Axsome Therapeutics, Biogen, Bristol Myers Squibb, Cognitive Research Corporation, Cognition Therapeutics, Eisai, IQVIA, Lundbeck, MapLight Therapeutics, Novartis, Novo Nordisk, ONO Pharma, Otsuka, WCG, WebMD, and Xenon. |
| Contracted research | Alector, Athira Pharma, Biogen, Cassava Sciences, Eisai, Eli Lilly, Genentech/Roche, and Vaccinex. | |
| Steve Bancroft | Nothing to disclose. | |
All relevant financial relationships have been mitigated.
Content Review
The content of this activity was independently peer reviewed by a physician and nurse reviewer.
Individuals in Control of the Content of the Activity
The individuals in control of the content of this activity have reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CE activity:
- Matthew Frese, MBA, CEO of Med Learning Group, has nothing to disclose.
- Lauren Welch, MA, Sr VP of Operations for Med Learning Group, has nothing to disclose.
- Sharine Griggs, Senior Program Manager for Med Learning Group, has nothing to disclose.
- Surabhi Dangi-Garimella, Ph.D., Medical Director for Med Learning Group has nothing to disclose.
- Tom Bregartner, MBA, VP of Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
- Nicole Love-Grove, DO, for Med Learning Group, has nothing to disclose.
- A medical reviewer from CME Peer Review LLC, has nothing to disclose.
- Daniel Dasilva, Accreditation and Outcomes Coordinator for Med Learning Group, has nothing to disclose.
- Emmanuella Foucault, Associate Program Manager for Med Learning Group, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CE credit for this activity. In order to obtain your certificate for the mentioned accreditation, participants need to successfully complete the associated pre/post activities and evaluation. Your certificate will be provided as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CE activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making expertise before applying any information, whether provided here or by others, for any professional use.
For CE questions, please contact Med Learning Group at [email protected]
Contact this CE provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Event staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]
RELEASED DATE: July 09, 2025
EXPIRATION DATE: July 09, 2026
Copyright © 2025 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.
PROGRAM CHAIR
Anton P. Porsteinsson, MD
William B. and Sheila Konar Professor of Psychiatry
Neurology, Neuroscience, and Medicine
Director, Alzheimer’s Disease Care, Research and Education Program (AD CARE)
University of Rochester School of Medicine and Dentistry
Rochester, New York
PATIENT
Thomas Mahoney, MD
Pittsford, New York
PROGRAM OVERVIEW
This program has been developed to educate health care practitioners who care for patients with Alzheimer’s disease on the importance of early diagnosis of mild cognitive impairment (MCI) due to Alzheimer’s disease, timely specialist referral, and effective treatment and monitoring of patients receiving anti-amyloid therapies. It highlights the importance of a multidisciplinary, shared decision-making approach to optimize care management. This Day in the Life docuseries provides unique insights into the patient’s journey from diagnosis to treatment and the physician’s perspective on the clinical strategies for managing disease symptoms.
TARGET AUDIENCE
This activity is designed to meet the educational needs of health care providers involved in the diagnosis and continued care of patients with Alzheimer’s disease, including primary care physicians, neurologists, geriatricians, psychiatrists, and other multidisciplinary team members.
LEARNING OBJECTIVES
On completing this program, attendees should be able to:
- Integrate evidence-based pathways for screening, diagnosing, and staging MCI and AD
- Appraise clinical practice recommendations informing use of DMTs for AD and identifying those who qualify for treatment based on available clinical data
- Assess and manage potential adverse events associated with DMTs for AD using a multidisciplinary approach
- Develop practice protocols to improve access to DMTs for AD
- Apply best practices for shared decision making when discussing DMT treatment for AD, including discussions of treatment benefits, risks, and what to expect with therapy
JOINT ACCREDITATION STATEMENT
In support of improving patient care, Med Learning Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 0.50 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
NURSES (ANCC) CREDIT DESIGNATION
Med Learning Group designates this activity for a maximum of up to 0.50 ANCC contact hours.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIPS
| Speaker | Relationship | Manufacturer |
| Anton P. Porsteinsson, MD | Consultant | Acadia, Athira Pharma, Axsome Therapeutics, Biogen, Bristol Myers Squibb, Cognitive Research Corporation, Cognition Therapeutics, Eisai, IQVIA, Lundbeck, MapLight Therapeutics, Novartis, Novo Nordisk, ONO Pharma, Otsuka, WCG, WebMD, and Xenon. |
| Contracted research | Alector, Athira Pharma, Biogen, Cassava Sciences, Eisai, Eli Lilly, Genentech/Roche, and Vaccinex. | |
| Thomas Mahoney, MD | Nothing to disclose. | |
All relevant financial relationships have been mitigated.
Content Review
The content of this activity was independently peer reviewed by a physician and nurse reviewer.
Individuals in Control of the Content of the Activity
The individuals in control of the content of this activity have reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CE activity:
- Matthew Frese, MBA, CEO of Med Learning Group, has nothing to disclose.
- Lauren Welch, MA, Sr VP of Operations for Med Learning Group, has nothing to disclose.
- Sharine Griggs, Senior Program Manager for Med Learning Group, has nothing to disclose.
- Surabhi Dangi-Garimella, Ph.D., Medical Director for Med Learning Group has nothing to disclose.
- Tom Bregartner, MBA, VP of Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
- Nicole Love-Grove, DO, for Med Learning Group, has nothing to disclose.
- A medical reviewer from CME Peer Review LLC, has nothing to disclose.
- Daniel Dasilva, Accreditation and Outcomes Coordinator for Med Learning Group, has nothing to disclose.
- Emmanuella Foucault, Associate Program Manager for Med Learning Group, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CE credit for this activity. In order to obtain your certificate for the mentioned accreditation, participants need to successfully complete the associated pre/post activities and evaluation. Your certificate will be provided as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CE activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making expertise before applying any information, whether provided here or by others, for any professional use.
For CE questions, please contact Med Learning Group at [email protected]
Contact this CE provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Event staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]
RELEASED DATE: July 09, 2025
EXPIRATION DATE: July 09, 2026
Copyright © 2025 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.
